U.S. market Closed. Opens in 18 hours 53 minutes

PSTV | Plus Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.6700 - 1.8000
52 Week Range 0.9700 - 7.20
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 23,565
Average Volume 708,958
Shares Outstanding 4,522,660
Market Cap 8,140,788
Sector Healthcare
Industry Biotechnology
IPO Date 2001-07-11
P/E Ratio -0.31
Forward P/E Ratio N/A
EPS -5.87
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 17
Country USA
Website PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
*Chart delayed
Analyzing fundamentals for PSTV we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PSTV Fundamentals page.

Watching at PSTV technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on PSTV Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙